Dopamine Receptor Agonists: New Formulations and New Potentials in the Treatment of Parkinson’s Disease

Parkinson Hastalığı ve Atipik Parkinson Sendromlarının Ayırıcı Tanısı

“…Dopamine receptors can be individualized into two classifications, which are D1-like receptors: D1 and D5 and D2-like receptors in which all non-ergoline DRA bind: D2, D3 and D4 29 . D1 and D2 dopaminergic receptors are the main clinical receptors for movement and thus these medications act on the dopaminergic receptors to reduce tremors 41 .…”

“…The advantages of DRA over levodopa is direct stimulation in the substantia nigra specifically on the degenerating neurons of postsynaptic neuron receptors, a decreased risk of instability of motor movements, longer half-life than levodopa, the diminished competition for transport systems such as the gastrointestinal tract (GIT) or crossing the blood-brain-barrier 41 . Compared to levodopa, DRA have a lower risk of dyskinesias and a greater ability to reduce motor fluctuations 39 .…”

“…RTG is applied to the skin and it effectively works by maintaining a stable plasma concentration over 24 hours 18,43 . Rotigotine is a potent agonist that targets all dopamine receptors D1-D5 29,41 . A study conducted by Moretti et al, 2014, 51 PD patients with dementia, CBD, MSA, PSP, LBD and frontotemporal dementias were treated with RTG for 6 months-18months.…”